NYSE:CRL - New York Stock Exchange, Inc. - US1598641074 - Common Stock - Currency: USD
CHARLES RIVER LABORATORIES
NYSE:CRL (1/29/2025, 8:15:40 PM)
After market: 161.64 0 (0%)161.64
-2 (-1.22%)
The current stock price of CRL is 161.64 USD. In the past month the price decreased by -13.17%. In the past year, price decreased by -25.91%.
Top movers analysis one hour before the close of the markets of S&P500 on 2025-01-16: top gainers and losers in today's session.
Which S&P500 stocks are moving on Thursday?
Looking for the S&P500 stocks that are experiencing notable gaps on Thursday? Find out which stocks are gapping up and gapping down in the S&P500 index during today's session.
As we await the opening of the US market on Thursday, let's delve into the pre-market session and discover the S&P500 top gainers and losers shaping the early market sentiment.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
TMO | THERMO FISHER SCIENTIFIC INC | 26.52 | 217.35B | ||
DHR | DANAHER CORP | 29.87 | 161.60B | ||
A | AGILENT TECHNOLOGIES INC | 27.81 | 41.95B | ||
IQV | IQVIA HOLDINGS INC | 18.24 | 35.95B | ||
MTD | METTLER-TOLEDO INTERNATIONAL | 35.01 | 28.18B | ||
WST | WEST PHARMACEUTICAL SERVICES | 50.23 | 24.59B | ||
WAT | WATERS CORP | 35.48 | 24.00B | ||
ILMN | ILLUMINA INC | 76.14 | 20.89B | ||
ICLR | ICON PLC | 14.12 | 16.36B | ||
RVTY | REVVITY INC | 26.11 | 15.03B | ||
AVTR | AVANTOR INC | 21.93 | 14.63B | ||
TECH | BIO-TECHNE CORP | 40.13 | 11.41B |
Charles River Laboratories International, Inc. engages in providing products and services to help pharmaceutical and biotechnology companies. The company is headquartered in Wilmington, Massachusetts and currently employs 20,000 full-time employees. The company went IPO on 2000-06-23. The firm's Research Models and Services segment is comprised of three businesses that provide foundational tools that enables its clients to discover new molecules: Research Models, Research Model Services, and Cell Solutions. Its Discovery and Safety Assessment segment provides regulated and non-regulated DSA services to support the research, development, and regulatory-required safety testing of potential new drugs, including therapeutic discovery and optimization plus in vitro and in vivo studies, laboratory support services, and strategic non-clinical consulting and program management to support product development. Its Manufacturing Solutions segment includes Microbial Solutions and Biologics Solutions.
CHARLES RIVER LABORATORIES
251 Ballardvale St
Wilmington MASSACHUSETTS 01887 US
CEO: James C. Foster
Employees: 21100
Company Website: https://www.criver.com/
Investor Relations: https://ir.criver.com
Phone: 17812226000
The current stock price of CRL is 161.64 USD.
The exchange symbol of CHARLES RIVER LABORATORIES is CRL and it is listed on the New York Stock Exchange, Inc. exchange.
CRL stock is listed on the New York Stock Exchange, Inc. exchange.
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for CRL, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of CRL.
CRL does not pay a dividend.
CRL will report earnings on 2025-02-12, after the market close.
The PE ratio for CRL is 15.97. This is based on the reported non-GAAP earnings per share of 10.12 and the current share price of 161.64 USD.
The outstanding short interest for CRL is 4.46% of its float.
ChartMill assigns a fundamental rating of 5 / 10 to CRL. While CRL belongs to the best of the industry regarding profitability, there are concerns on its financial health.
Over the last trailing twelve months CRL reported a non-GAAP Earnings per Share(EPS) of 10.12. The EPS decreased by -9.4% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | 10.17% | ||
ROA | 5.16% | ||
ROE | 10.92% | ||
Debt/Equity | 0.62 |
ChartMill assigns a Buy % Consensus number of 67% to CRL. The Buy consensus is the average rating of analysts ratings from 25 analysts.
For the next year, analysts expect an EPS growth of -3.27% and a revenue growth -1.71% for CRL